Search results for "Highlights"
Halting one ulcerative colitis treatment after escalating to new drug may be feasible, study finds
Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
https://gastroenterology.acponline.org/archives/2018/11/27/3.htm
27 Nov 2018
COVID-19 guidance released for managing IBD patients, endoscopic procedures
The American Gastroenterological Association released new guidance for clinicians caring for patients with inflammatory bowel disease (IBD) and those performing endoscopic procedures, and two recent studies looked at GI symptoms in patients with COVID-19.
https://gastroenterology.acponline.org/archives/2020/04/24/1.htm
24 Apr 2020
Rates of HDV co-infection may be higher than previously estimated
Patients with chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) co-infection have the most severe form of viral hepatitis and are at much higher risk for cirrhosis and hepatocellular cancer than patients with HBV infection alone.
https://gastroenterology.acponline.org/archives/2018/09/28/3.htm
28 Sep 2018
Induction, maintenance therapies for ulcerative colitis compared
Oral sulfasalazine, diazo-bonded 5-aminosalicylates (5-ASAs), mesalazine, controlled ileal-release budesonide, and budesonide multimatrix, alone or in combination with rectal 5-ASA therapy, were assessed for comparative efficacy and tolerability.
https://gastroenterology.acponline.org/archives/2018/08/24/3.htm
24 Aug 2018
Score predicts hepatic decompensation among patients with NAFLD
Age, presence of diabetes, and platelet count were significant predictors of hepatic events up to 12 years from the time of nonalcoholic fatty liver disease (NAFLD) diagnosis, a retrospective study found.
https://gastroenterology.acponline.org/archives/2020/03/27/1.htm
27 Mar 2020
Guideline offers recommendations on anticoagulation, thromboses in vascular liver disorders
Among other guidance, the American College of Gastroenterology recommends anticoagulation for all patients without cirrhosis who have acute symptomatic portal vein thrombosis or mesenteric vein thrombosis in the absence of any contraindication.
https://gastroenterology.acponline.org/archives/2020/01/24/1.htm
24 Jan 2020
Beta-blocker monotherapy may be preferred for primary prophylaxis of esophageal variceal bleeding
Guidelines currently recommend nonselective beta-blockers or variceal band ligation for primary prevention of variceal bleeding based on similar efficacy, but survival benefit may be better with the former treatment.
https://gastroenterology.acponline.org/archives/2018/08/24/2.htm
24 Aug 2018
Boxed warning added to liver disease drug
The drug has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis, which increases the risk of serious liver injury, the FDA said.
https://gastroenterology.acponline.org/archives/2018/02/23/7.htm
23 Feb 2018
Early-onset colorectal cancer increases sharply between ages 49 and 50, study finds
According to U.S. registry data, incidence of colorectal cancer increased 46.1% from age 49 years to age 50 years, from 34.9 to 51.0 per 100,000 population.
https://gastroenterology.acponline.org/archives/2020/02/28/1.htm
28 Feb 2020
Guidance issued for comanagement of COVID-19 GI, liver manifestations
Two meta-analyses, one of them from the American Gastroenterological Association (AGA), found that GI symptoms and liver abnormalities are not uncommon in patients with COVID-19. The AGA issued a series of best practice statements based on its findings.
https://gastroenterology.acponline.org/archives/2020/05/22/1.htm
22 May 2020